NFO period: 19^th November - 03^rd December, 2024

Highlights of the NFO:

• Scheme type - An open ended equity scheme investing in healthcare and pharmaceutical sector


• Investment objective - The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there is no assurance that the investment objective of the scheme will be achieved. The scheme does not guarantee/ indicate any returns.


• Product suitability - This product is suitable for investors who are seeking long term capital growth by investing in equity and equity related securities of pharmaceutical and healthcare companies.


• Minimum Application Amount - First investment is Rs. 5,000/- and in multiples of Rs. 1/- thereafter


• Plan/ Options available - Regular Plan & Direct Plan having Growth Option and Income Distribution cum Capital Withdrawal (IDCW) Option. IDCW Option has the following two facilities: Payout of Income Distribution cum Capital Withdrawal facility (IDCW-Payout) and Reinvestment of Income Distribution cum Capital Withdrawal facility (IDCW- Reinvestment).


• Fund Managers - Mr. Anandha Padmanabhan Anjeneyan, Mr. Utsav Mehta, Mr. Vivek Sharma and Mr. Puneet Pal


• Benchmark - BSE Healthcare TRI